Published on November 17, 2009 at 8:04 AM
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced today that Professor John F. Thompson, MD, Professor of Melanoma and Surgical Oncology at the University of Sydney, Director of the Melanoma Institute Australia, and Lead Investigator of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November 21, 2009 in Berlin, Germany.
In his presentation entitled “PV-10 in the Local Treatment of Melanoma Metastasis,” Professor Thompson will be presenting overall survival data for the Phase 1 and Phase 2 trials as well as an update on data from the expanded access use of PV-10 in Australia and the United States (“Compassionate Use”). Provectus expects to issue a press release to update shareholders and the medical and scientific community regarding the data early next week after the completion of the presentation.
Craig Dees, PhD, CEO of Provectus said, “We are excited about Professor Thompson’s presentation, which will be the first time that interim survival data for the Phase 2 trial will be presented. Further, his discussion will provide the first look at the progress that has been made with our expanded access program for PV-10, the means through which certain qualified patients can receive PV-10 on a compassionate use basis, in Australia and the United States. Both of these aspects of his presentation are certain to be very enlightening on the topic of PV-10’s continued development.”
Source Provectus Pharmaceuticals, Inc.
1e4e8117-84c9-490f-b3e0-d09c1aace944|1|5.0
Posted in: Drug Trial News | Medical Condition News
Tags: Apoptosis, Atopic Dermatitis, Breast Cancer, Cancer, Cell, Dermatitis, Dermatology, Evolution, Liver Cancer, Melanoma, Metastasis, Oncology, Psoriasis, Skin Cancer